Literature DB >> 1418831

Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension.

F Facchini1, Y D Chen, C Clinkingbeard, J Jeppesen, G M Reaven.   

Abstract

Various facets of glucose, insulin, and lipid metabolism were compared in 76 normal volunteers--38 with and 38 without a family history of hypertension. The two groups were comparable in terms of age, gender distribution, and degree of obesity (both generalized and abdominal). Although the plasma glucose response to oral glucose was similar in both groups, glucose-stimulated insulin concentrations were significantly greater in volunteers with a family history of hypertension (P < .001). Furthermore, the steady state plasma glucose concentration during a constant infusion of glucose, insulin and somatostatin was significantly greater in subjects with a family history of hypertension (8.1 +/- 0.6 v 6.2 +/- 0.6 mmol/L, P < .001). Since the steady-state plasma insulin levels during the infusion were similar, these results indicate that normotensive individuals with a family history of hypertension are relatively insulin resistant. Finally, plasma very low density lipoprotein (VLDL) triglyceride and VLDL cholesterol were higher in those with a family history of hypertension, as was the ratio of total to high density lipoprotein cholesterol. Thus, normotensive individuals with a family history of high blood pressure are insulin resistant, hyperinsulinemic and dyslipidemic when compared to a matched group of healthy volunteers without a family history of hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418831     DOI: 10.1093/ajh/5.10.694

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  The insulin resistance syndrome.

Authors:  Gerald M Reaven
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

2.  Plasma adiponectin and insulin resistance in new onset hypertension.

Authors:  Teoman Dogru; Alper Sonmez; Ilker Tasci; M Ilker Yilmaz; Selim Kilic; Taner Ozgurtas; Tayfun Eyileten; M Kemal Erbil; I Hakki Kocar
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 3.  Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease.

Authors:  G M Reaven; A Laws
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

4.  Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test.

Authors:  D Pei; C N Jones; R Bhargava; Y D Chen; G M Reaven
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

5.  Changes in socio-economic status and lipoproteins in Chilean adolescents: a 16-year longitudinal study.

Authors:  Zachary J Madewell; Estela Blanco; Raquel Burrows; Betsy Lozoff; Sheila Gahagan
Journal:  Public Health Nutr       Date:  2018-11-26       Impact factor: 4.022

6.  Insulin resistance in Nigerians with essential hypertension.

Authors:  T O Akande; J O Adeleye; S Kadiri
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

7.  Serum lipid and lipoprotein levels in Ghanaians with diabetes mellitus and hypertension.

Authors:  A Nyarko; K Adubofour; F Ofei; J Kpodonu; S Owusu
Journal:  J Natl Med Assoc       Date:  1997-03       Impact factor: 1.798

8.  Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension.

Authors:  M Pravenec; V Zidek; M Simakova; V Kren; D Krenova; K Horky; M Jachymova; B Mikova; L Kazdova; T J Aitman; P C Churchill; R C Webb; N H Hingarh; Y Yang; J M Wang; E M Lezin; T W Kurtz
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 9.  The pathogenesis of hypertension in obese subjects.

Authors:  P Weidmann; M de Courten; L Boehlen; S Shaw
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Insulin resistance, hypertension, and coronary heart disease.

Authors:  Gerald Reaven
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.